SEARCH LISTED COMPANY
ANY AUS OR NZ COMPANY
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
FROM | TO | |
---|---|---|
APOLLO LIFE SCIENCES LIMITED | 09/09/2009 |
Level 17, 221 St Georges Terrace, Perth WA 6000
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)many shareholders in this company have unclaimed money due to them - deListed provides a tracing service for a small administration fee that identifies where people can find unclaimed monies arising from compulsory acquisitions and also from dividend distributions, super contributions, inoperative bank, building society or credit union accounts, bequests and other sources - please click here for access to our Lost shares, Lost money service | 22/03/2023 |
delisted following compulsory acquisition under Listing Rule 17.14 | 17/12/2021 |
we understand Ramelius Resources Limited was successful with an offer of $0.34 cash and 0.1778 Ramelius shares for each Apollo share | 17/12/2021 |
The securities of Apollo Consolidated Limited will be suspended from quotation at the close of trading today, Monday, 13 December 2021, in accordance with Listing Rule 17.4, following despatch of the compulsory acquisition notices by Ramelius Resources Limited. | 13/12/2021 |
Apollo Consolidated Limited (the "Company") will be reinstated to official quotation as from the commencement of trading on Wednesday, 11 April 2012, following the Company" compliance with listing rule 11.1.3 and chapters 1 and 2 of the ASX listing rules | 10/04/2012 |
releases Half Year Accounts | 14/03/2012 |
lodges third Supplementary Prospectus | 01/03/2012 |
lodges second Supplementary Prospectus dated 27 February 2012 | 27/02/2012 |
issues supplementary prospectus | 21/02/2012 |
releases a prospectus inviting applications for 10,000,000 Shares at an issue price of $0.20 per Share to raise $2,000,000. The Company may accept oversubscriptions of up to a further 2,500,000 Shares at an issue price of $0.20 per Share to raise up to a further $500,000 | 08/02/2012 |
reports that during the December quarter, the company moved toward finalisation of the Aspire Cote d'Ivoire transaction as announced to ASX on September 6, 2011 At a general meeting held on December 23, 2011, shareholders voted overwhelmingly to approve the Transaction and to change the nature of the activities of the company to focus on gold exploration at its Ivorian projects and on the advanced Rebecca Project. | 01/02/2012 |
releases a shareholder presentation | 24/01/2012 |
company advises that it has appointed BBY Limited (BBY) as sponsoring broker to the Company's offer of 10,000,000 new fully paid ordinary shares at an issue price of $0.20 per share (Offer) to raise up to $2,000,000 (before costs). Under the terms of the Offer, which is not underwritten, the Company may also accept oversubscriptions of up to 2,500,000 further shares at $0.20 per share to raise an additional $500,000 | 24/01/2012 |
we understand that on or about this date the company consolidated its shares 1 for 30 | 31/12/2011 |
all resolutions considered at the General Meeting were passed on a show of hands - trading in the Company's securities will remain suspended pending compliance with Chapters 1 & 2 of the Listing Rules, including lodgement of a prospectus (Prospectus) and completion of the placement of shares approved by the meeting (Placement). Preparation of the Prospectus is well advanced and it is now expected that this will be lodged in mid-January 2012 | 23/12/2011 |
the securities of Apollo Consolidated Limited (the "Company") will be suspended from official quotation from the commencement of trading on Friday 23 December 2011, pending the outcome of a resolution at the Company's general meeting to approve a change in the nature of the Company's activities. The Company's securities will remain suspended pending compliance with Chapters 1 and 2 of the Listing Rules | 22/12/2011 |
Apollo Consolidated reported negative cash flow of $93,000 for quarter ended 30 September 2011. Operating cash flow for the period was $(83,000). Investing cash flow was $(10,000). Financing cash flow was nil. Cash in hand at the end of the quarter was $1.4m | 17/10/2011 |
the securities of Apollo Consolidated Limited (the "Company") will be suspended from quotation immediately, following the announcement of the Company's proposed change of activities and its recompliance with chapters 1 and 2 of the Listing Rules | 06/09/2011 |
the suspension of trading in the securities of Apollo Consolidated Limited (the "Company") will be lifted before the commencement of trading on Wednesday, 7 September 2011, following the announcement by the Company of its proposed change of activities and its re-compliance with chapters 1 and 2 of the Listing Rules | 06/09/2011 |
securities reinstated to quotation | 07/10/2009 |
releases Half Year Accounts to 31 December 2008 | 06/10/2009 |
offers under the Company's prospectus dated 4 September 2009 ("Prospectus") have closed, oversubscribed. Shares have now been allotted and Apollo's directors resolved to accept the maximum number of oversubscriptions permitted under the Prospectus General Offer, being an additional 120,000,000 shares | 05/10/2009 |
the deed of company arrangement has been effectuated and control of the company reverts to its directors | 02/10/2009 |
issues a supplementary prospectus | 30/09/2009 |
name changed from Apollo Life Sciences Limited | 09/09/2009 |
DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
---|---|---|---|---|
18/04/2018 | Anthony James | 75,000 | $0.260 | $19,500.00 |
19/03/2018 | Stephen West | -300,000 | $0.250 | $75,000.00 |
05/07/2012 | Nick Castleden | 200,000 | $0.100 | $20,000.00 |
NAME | TITLE | DATE OF APPT |
---|---|---|
Roger Steinepreis | Chairman | 04/08/2009 |
Nick Castleden | Managing Director, CEO | 04/08/2009 |
Tim Manners | Director | 22/11/2021 |
Bob Vassie | Director | 22/11/2021 |
Mark Zeptner | Director | 22/11/2021 |
Alex Neuling | Company Secretary | |
Richard Jones | Company Secretary |
Date of first appointment, title may have changed.
NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
---|
Date of first appointment, title may have changed.